One reason for the reduced efficiacy is innate resistance, where individuals may have tumours that lack T cells, so anti-PD-1/PD-L1 ICBs are ineffective, since their target (i.e., T cells) is absent from the TME. The gene discussed is CD274; the disease is neoplasm.